Related Experiment Videos
Oligodendroglioma: does deferring treatment compromise outcome?
Steven J Feigenberg1, Robert J Amdur, Christopher G Morris
1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA.
American Journal of Clinical Oncology
|June 11, 2003
Summary
Younger age and smaller tumor size are key factors for better outcomes in oligodendroglioma patients. Aggressive treatment deferral is safe for select young patients with specific symptoms, showing age is the most critical predictor of survival.
Area of Science:
- Neuro-oncology
- Neurosurgery
- Radiation Oncology
Background:
- Oligodendrogliomas are primary brain tumors with variable prognoses.
- Identifying factors predicting favorable outcomes is crucial for treatment planning.
Purpose of the Study:
- To identify factors predicting favorable outcomes in patients with oligodendroglioma.
- To analyze the University of Florida's experience in treating oligodendrogliomas.
Main Methods:
- Retrospective analysis of 51 patients diagnosed with pure oligodendroglioma between 1958 and 1998.
- Evaluation of treatment modalities including surgery, radiotherapy, and chemotherapy.
- Multivariate analysis to determine significant prognostic factors.
Main Results:
- Younger age (especially <21 years) and smaller tumor size (<5 cm) were significant predictors of improved absolute survival.
- Deferring aggressive treatment did not negatively impact survival for a select group of patients.
- Patients presenting with seizures alone had a statistically significant favorable outcome.
Conclusions:
- Age is the most important predictor of long-term progression-free and absolute survival in oligodendroglioma.
- Aggressive treatment may lead to cure in approximately one-third of patients.
- Selective deferral of treatment is viable for young patients with specific clinical and radiological presentations.